Why The Drive For Medical Transition Should Be Re-Psychopathologized (#42)
9 October 2025
Global
Genspect has launched a campaign calling for the re-psychopathologization of the drive toward medical gender transition, fifteen years after WPATH's 2010 statement dismantled psychiatric safeguards. Mia Hughes and Stella O'Malley draw a clinical distinction between holding a trans identity and the escalating, harm-directed behaviours that warrant professional scrutiny. Their argument maps closely onto the Cass Review's conclusion that NHS England's paediatric gender services failed to embed adequate mental health assessment — and onto the NHS's subsequent shift toward a model in which psychiatric evaluation comes first.
In this episode, Mia Hughes and Stella O'Malley examine Genspect's campaign to restore psychiatric oversight around the drive for medical gender transition — a direct challenge to the trajectory set by global bodies including WPATH, the American Psychiatric Association and the World Health Organisation over the past fifteen years. The argument traces back to 2010, when WPATH published its de-psychopathologization statement, declaring gender-variant identities natural and healthy and calling for the removal of psychiatric categorisation. The DSM-5 followed in 2013, retiring Gender Identity Disorder in favour of Gender Dysphoria — a shift that located pathology solely in a person's distress rather than in any behaviour or trajectory. By 2018, the WHO's ICD-11 went further, relocating gender incongruence out of mental health entirely and into a section on sexual health. Each step removed a layer of clinical scrutiny. Hughes and O'Malley argue that these reclassifications had direct practical consequences, stripping away the gatekeeping that might have slowed or questioned referrals of young people into pathways involving puberty blockers, cross-sex hormones and surgery. The campaign's central distinction matters: holding a trans identity is not, the hosts argue, inherently pathological. It is when that identity becomes expressed as an escalating, obsessive drive toward permanent removal of healthy tissue and irreversible endocrine disruption that the behaviour warrants mental health support — not accelerated medical referral. From a UK perspective, the case resonates strongly with the Cass Review, published in April 2024. Dr Hilary Cass concluded that NHS paediatric gender medicine had been built on an inadequate evidence base, that the therapeutic component of care had been systematically underdeveloped, and that young people with complex presentations had too often been channelled toward medical pathways without sufficient exploration of underlying mental health needs. NHS England subsequently suspended puberty blocker prescriptions for under-eighteens outside research settings, and the new service model places specialist mental health assessment at the centre of any clinical pathway. These changes represent, in practice, a partial restoration of the oversight that de-psychopathologization spent more than a decade dismantling. The Genspect campaign frames this not as stigmatising trans-identified people but as applying standard psychiatric principles: that a pattern of behaviour harmful to the individual, escalating and resistant to other interventions, warrants clinical attention. The hosts draw on the concept of extreme overvalued beliefs — a psychiatric framework from forensic and clinical contexts — to explain why a single-minded drive toward body modification in vulnerable adolescents fits an established clinical pattern that mental health professionals are trained to recognise and treat. Whether WPATH and the WHO will revise their frameworks in response to accumulating evidence from systematic reviews — including those commissioned by NHS England and equivalent bodies in Sweden and Finland — remains an open question. This episode sets out why the intellectual and ethical case for doing so is stronger than it has ever been.
